Rialto Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Rialto Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$332	Buy	+54	New	+$449	﹤0.01%	1519

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rialto Wealth Management's DNA Position: Q1 2026 in Review

Rialto Wealth Management opened a new position in Ginkgo Bioworks (DNA) in Q1 2026: 54 shares worth $332. The stake represents ﹤0.01% of the portfolio and ranks #1519 among its holdings.

174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Rialto Wealth Management held 54 shares of Ginkgo Bioworks worth $332 as of Q1 2026.
Ginkgo Bioworks was a new Rialto Wealth Management position in Q1 2026.
Ginkgo Bioworks made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1519 holding.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.